Measuring P2X4 receptors on blood monocytes to help diagnose ALS
Official title: Interest of Measuring P2X4 Receptors on Blood Monocytes as a Diagnostic Marker in Amyotrophic Lateral Sclerosis: P2X4 as a Diagnostic Biomarker for ALS
Run by University Hospital, Bordeaux · NCT07091799 · Data updated 2026-11-12
We will test whether measuring P2X4 receptors on blood monocytes can help diagnose ALS in adults with suspected or confirmed disease.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | University Hospital, Bordeaux Academic / other |
| Locations | 1 site (Bordeaux) |
| Status | Recruiting |
| Started | January 15, 2026 |
| Main results expected | January 2027 |
| Study ends | July 2027 |
| Registry record updated | January 21, 2026 |
| Trial ID | NCT07091799 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with a probable or confirmed diagnosis of ALS by El Escorial criteria, who can provide informed consent and are not taking immunosuppressive or corticosteroid medications, are the ideal candidates.
✕Probably not a fit
People on immunosuppressive or corticosteroid treatments, those unable to give consent, individuals under guardianship, and close relatives of patients (for healthy volunteer arm) are not eligible and unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Researchers will collect blood samples from adults with probable or confirmed ALS, from people with other neuromuscular disorders, and from healthy volunteers, then measure P2X4 receptor levels on monocytes. The study aims to confirm prior laboratory findings that the P2X4 purinergic pathway is linked to ALS and to provide a proof of concept for a blood-based biomarker. Participants on immunosuppressive or corticosteroid treatments, those in experimental treatment protocols, or individuals under legal protection are excluded. The work is conducted at Hôpital Pellegrin, University Hospital of Bordeaux, using standardized blood sampling and receptor quantification methods.
Why it matters
Potential benefit: If successful, this could lead to a simple blood test that helps clinicians diagnose ALS earlier and more accurately.
How similar studies have gone: This is a novel clinical application: laboratory studies suggest a role for P2X4 in ALS but clinical validation of P2X4 as a diagnostic biomarker is not yet established.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * For ALS group: Person presenting a probable or confirmed diagnosis of ALS according to the criteria of EI Escorial. * Adult. * Person affiliated or beneficiary of a social security scheme. * Free, informed and written consent signed by the participant or by a third person (in case of physical incapacity of the participant), after information on the study. Exclusion Criteria: * People undergoing immunosuppressive or corticosteroid treatments. * Participation in a research protocol with an experimental treatment. * People placed under guardianship, curatorship or legal protection. * For healthy volunteer, people directly related to the patient (siblings, descendants and ancestry).
Where it's running
-
Hôpital Pellegrin
Bordeaux, France Recruiting
Study contacts
- Study coordinator: Gwendal Le Masson, Pr
- Email: gwendal.le-masson@chu-bordeaux.fr
- Phone: 05 57 82 13 70
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
How upper-limb assistive devices affect users' daily life
This project will see if using a CE-marked upper-limb assistive device helps adults with stroke, spinal cord injury, or neuromuscular disorders improve independence, satisfaction, and social participation.
-
Using wearable sensors to monitor muscle activity in infants
This study is testing if wearable sensors can help track muscle activity in infants to spot any unusual muscle tone early on.
-
Customizing AFO stiffness for better walking in neuromuscular disorders
This study is testing if a custom-made ankle-foot brace with adjustable stiffness can help people with neuromuscular disorders walk better and feel safer compared to standard braces.
-
Gaze-Driven Neck Exoskeleton to Help Head-Neck Movements in ALS
This study tests a powered neck exoskeleton with gaze-based controls to see if it helps people with ALS who have head drop.
-
Implanted Brain-Computer Interface to Help People with Severe Arm Impairment
We’re testing the N1 System, a fully implanted brain interface in the motor cortex with a robot, to see if it can help adults with spinal cord injury, ALS, or chronic stroke use a computer or keyboard more easily.
-
Brain-computer interface chat tool for people with ALS
This test compares a wearable brain-computer interface communication device to eye-tracking devices that people with ALS currently use to help them communicate.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.